Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors
- 11 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 92 (1097) , 20181006
Abstract
Objective: To assess the role of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET), obtained before and during chemoradiotherapy, in predicting locoregional failure relative to clinicopathological factors for patients with anal cancer. Methods: 93 patients with anal squamous cell carcinoma treated with chemoradiotherapy were included in a prospective observational study (NCT01937780). FDG-PET/CT was performed for all patients before treatment, and for a subgroup (n = 39) also 2 weeks into treatment. FDG-PET was evaluated with standardized uptake values (SUVmax/peak/mean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and a proposed Z-normalized combination of MTV and SUVpeak (ZMP). The objective was to predict locoregional failure using FDG-PET, tumor and lymph node stage, gross tumor volume (GTV) and human papilloma virus (HPV) status in univariate and bivariate Cox regression analysis. Results: N3 lymph node stage, HPV negative tumor, GTV, MTV, TLG and ZMP were in univariate analysis significant predictors of locoregional failure (p < 0.01), while SUVmax/peak/mean were not (p > 0.2). In bivariate analysis HPV status was the most independent predictor in combinations with N3 stage, ZMP, TLG, and MTV (p < 0.02). The FDG-PET parameters at 2 weeks into radiotherapy decreased by 30–40 % of the initial values, but neither absolute nor relative decrease improved the prediction models. Conclusion: Pre-treatment PET parameters are predictive of chemoradiotherapy outcome in anal cancer, although HPV negativity and N3 stage are the strongest single predictors. Predictions can be improved by combining HPV with PET parameters such as MTV, TLG or ZMP. PET 2 weeks into treatment does not provide added predictive value. Advances in knowledge: Pre-treatment PET parameters of anal cancer showed a predictive role independent of clinicopathological factors. Although the PET parameters show substantial reduction from pre- to mid-treatment, the changes were not predictive of chemoradiotherapy outcome.Keywords
This publication has 46 references indexed in Scilit:
- Australasian Gastrointestinal Trials Group (AGITG) Contouring Atlas and Planning Guidelines for Intensity-Modulated Radiotherapy in Anal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancerRadiotherapy and Oncology, 2012
- FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapyBritish Journal of Cancer, 2011
- Prognostic factors derived from a prospective database dictate clinical biology of anal cancerCancer, 2010
- Accurate Prediction of Pathological Rectal Tumor Response after Two Weeks of Preoperative Radiochemotherapy Using 18F-Fluorodeoxyglucose-Positron Emission Tomography-Computed Tomography ImagingInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosisRadiotherapy and Oncology, 2010
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Tumor Response and Survival Predicted by Post-Therapy FDG-PET/CT in Anal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Patterns of local disease failure and outcome after salvage surgery in patients with anal cancerBritish Journal of Surgery, 2005